Versatope Awarded Grant for a Novel C. diff Vaccine
Sep 8, 2020
LOWELL, Mass., Sept. 9, 2020 /PRNewswire/ -- Versatope Therapeutics, Inc., a biotechnology company developing vaccines and therapeutics, announced today that it has been awarded a Phase 1 Small Business and Innovation Award from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH) to develop a novel vaccine for the prevention and possible treatment for Clostridioides difficile, also known as C. diff.
C. diff is a bacterium that causes diarrhea and colitis (an inflammation of the colon). According to the Centers for Disease Control (CDC), there are about 500,000 cases in the United States annually, with almost 20% infection recurrence within 2-8 weeks. Approximately 1 in 11 infected people over the age of 65 die of the C. diff infection, or 15,000 people per year. The NIAID grant will support Versatope's goal of producing a C. diff vaccine designed to protect against recurring disease by using exosome-like bacterial vesicles. NIAID funding will support early stage manufacturing, stability and preclinical studies to demonstrate safety and tolerability.
"The support from NIAID will enable Versatope to apply its bioinformatic and structure-based vaccine approach to new bacterial infection targets and deliver novel C. diff vaccine candidates," said Christopher Locher, Ph.D., CEO of Versatope Therapeutics, Inc.
"We are proud to have Versatope as an M2D2 resident company. They are a talented, top-notch team and it is very rewarding to watch their successes as they develop a novel vaccine technology," said Mary Ann Picard, University of Massachusetts Lowell – Director of Operations, M2D2.
"I am excited that Versatope has received this well-deserved funding for their program for preventing C. difficile infection and recurrence. I look forward to working with them for the development of a vaccine to treat the urgent threat of this pathogen," said William J. Weiss, University of North Texas College of Pharmacy, Director of Preclinical Services.
"We are proud to have Versatope as part of the Massachusetts life sciences community and look forward to their successes as they advance their cutting-edge vaccine technology for patients around the world," said Robert K. Coughlin, President & CEO of MassBio.
This project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institute of Health, Department of Health and Human Services, under Award no. R43AI149901, entitled, "Novel C. Difficile Vaccine Using Nano-vesicle Delivery System."
About Versatope Therapeutics Versatope Therapeutics, Inc., is a start-up biotechnology company based at the University of Massachusetts M2D2 focused on the development of an immunotherapy platform using recombinant vesicles from probiotic bacteria. The company combines bioinformatics, synthetic biology, chemistry, and leverages the therapeutic applications of the rOMV technology to create new vaccines and therapeutics. Learn more about Versatope Therapeutics at www.versatope.com and on Twitter @VersatopeRx.
Versatope Contact: Christopher Locher, PhD, CEO
+1 781 879-3119
[email protected]
SOURCE Versatope Therapeutics
Related Links
More News
DoorDash to Buy Instacart for $17 Billion, Uniting 2 Delivery Giants
The deal combines the country’s largest restaurant delivery service with its biggest online grocery platform.
U.S. GDP Increased 3.4% in Third Quarter
The economy grew 3.4 percent in the third quarter, the fastest pace in a year. Strong spending and growth contrast with the poor marks many voters are giving the economy.
How to Plan a Trip Around a Running Race
When should you arrive? How do you choose an event? Here are some tips on how best to center a vacation around a race.
Island Energy: No plans to remove gas standing charge
The provider said any change would need support from the community, the regulator and government.
In Moving Gradually, Fed Risks Having to Play Catch-Up to Quell Inflation
Federal Reserve officials are expected to restart rate increases in December, but the cadence of additional moves will depend on the data.
Minimum wage rise 'a massive blow' says farmer
Tristan Bennett voices his disappointment in the Budget, describing it as "a lot of tinkering".
Minimum wage increase accepted by minister
A recommendation to increase the minimum wage by 2.8% is agreed by Senator Elaine Millar.
'Painful' years ahead, think tanks warn, as living standards set to fall
Budget forecasts show growth in living standards grinding almost to a halt.
RFK Jr. to Allow Broad Use of Unapproved Peptide Injections
In a unilateral declaration by the health secretary, several injections promoted by online influencers will become widely available. The F.D.A. had advised against the move.
Microsoft Up, Google Down. A Tale of Two Hyperscalers.
Investors are showing little patience for lavish spending and meager returns on companies’ artificial intelligence bets.
I earn £30,000. I'm angry there was no fuel duty cut in the Budget
People on a range of incomes from £4,062 to £150,000 a year tell the BBC what they made of this year's Budget.
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.